Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Batoclimab in Myasthenia Gravis: NCT05039190 Clinical Landscape Report 2026
16 October 2026
NCT05039190 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Apraclonidine Hydrochloride in Myasthenia Gravis: NCT05045248 Clinical Landscape Report 2026
16 October 2026
NCT05045248 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LB-P8 in Metabolic Dysfunction Associated Steatohepatitis: NCT05053165 Clinical Landscape Report 2026
16 October 2026
NCT05053165 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Yinfenidone Hydrochloride in Idiopathic Pulmonary Fibrosis: NCT05060822 Clinical Landscape Report 2026
16 October 2026
NCT05060822 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Latozinemab in Amyotrophic Lateral Sclerosis: NCT05053035 Clinical Landscape Report 2026
16 October 2026
NCT05053035 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tocilizumab in Myasthenia Gravis: NCT05067348 Clinical Landscape Report 2026
16 October 2026
NCT05067348 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Emicizumab in Hematologic Diseases: CTRI/2021/09/036767 Clinical Landscape Report 2026
16 October 2026
CTRI/2021/09/036767 clinical landscape for Hematologic Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Denecimig in Hemophilia A: NCT05053139 Clinical Landscape Report 2026
16 October 2026
NCT05053139 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nitric oxide (inhaled) in Dyspnea: NCT05052229 Clinical Landscape Report 2026
16 October 2026
NCT05052229 clinical landscape for Dyspnea: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pozelimab in Myasthenia Gravis: NCT05070858 Clinical Landscape Report 2026
16 October 2026
NCT05070858 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Crovalimab in Anemia, Sickle Cell: NCT05075824 Clinical Landscape Report 2026
16 October 2026
NCT05075824 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Turoctocog alfa pegol in Hemorrhage: NCT05082116 Clinical Landscape Report 2026
16 October 2026
NCT05082116 clinical landscape for Hemorrhage: endpoints, sponsor, phase, geography, readouts, asset context and development white space.